Abdomen

HALO Precision Diagnostics Collaborating with Bayer to Advance Contrast-Enhanced MRI

Retrieved on: 
Tuesday, October 17, 2023
Biotechnology, Health, Radiology, Clinical Trials, Oncology, Cardiovascular disease, Partnership, Pharmacokinetics, Abdomen, Breast cancer, Pelvis, Central nervous system, Ageing, Safety, Thorax, R, Extremities, Neck, Head, MRI, Prostate cancer, Patient, HALO, Medical device, Medical imaging, Bayer

HALO Precision Diagnostics (“HALO”), a leader in early disease detection using precision diagnostics, today announced a collaboration with Bayer, ​​a global leader in radiology, to join QUANTI, Bayer’s Phase III clinical development program for gadoquatrane.

Key Points: 
  • HALO Precision Diagnostics (“HALO”), a leader in early disease detection using precision diagnostics, today announced a collaboration with Bayer, ​​a global leader in radiology, to join QUANTI, Bayer’s Phase III clinical development program for gadoquatrane.
  • Bayer initiated the QUANTI studies to evaluate the safety and efficacy of gadoquatrane, an investigational gadolinium-based contrast agent, in MRI.
  • Contrast-enhanced MRI plays a key role in the healthcare continuum, providing a radiation-free imaging method to obtain detailed images of the body.
  • “Our partnership with Bayer is the latest example of HALO leading the way when it comes to advancements supporting early disease detection,” said Bernadette Greenwood, chief research officer, HALO.

GE HealthCare Signs $44 Million Contract with BARDA to Develop Artificial Intelligence-Augmented Ultrasound Technology to Aid Clinicians in Diagnosing and Treating Traumatic Injury and Enhance National Preparedness for Mass Casualty Incidents

Retrieved on: 
Thursday, October 12, 2023
Radiology, White House, Federal Government, Artificial Intelligence, Medical Devices, Infectious Diseases, Hospitals, Homeland Security, Professional Services, Data Management, Technology, Public Policy, Government, General Health, Biotechnology, Data Analytics, Health, Law Enforcement, Emergency Services, Public Safety, Apps, Applications, Health Technology, Triage, Infection, Hospital, ASPR, Acquisition, Abdomen, Death, Development, Office of Inspector General, U.S. Department of Health and Human Services, Standard of care, Human services, AI, Administration for Strategic Preparedness and Response, Injury, Administration, Transfusion-related acute lung injury, Survival, Trauma, Artificial intelligence, Biomedical Advanced Research and Development Authority, GE, Head, GE HealthCare, BARDA, HHS, Patient, Medical imaging, Ultrasound

Trauma is a leading cause of death in the United States1 posing an enormous burden to healthcare systems and society.

Key Points: 
  • Trauma is a leading cause of death in the United States1 posing an enormous burden to healthcare systems and society.
  • Injury detection and triage of trauma patients play key roles in successful patient care and resource management, both in everyday situations and in mass casualty events.
  • Technologies that expedite care, including detection, evaluation, and decision-assist capabilities, potentially increase patients’ chances of survival.
  • “Point-of-care ultrasound is an essential tool in emergency situations to help clinicians quickly get the answers they need when treating patients,” said Roland Rott, President and CEO, Ultrasound, GE HealthCare.

Cost of living crisis: Burns to children from hot water bottles have increased by 45% reported by Children's Burns Trust

Retrieved on: 
Wednesday, October 11, 2023
Parent, Pain, Ambulance, Burn, Abdomen, Accident, Table tennis rubber, FRCS, Emergency, Injury, Ibid., Temperature, Trust, Neck, Burns, CALL, Scalding, Life, Water, Propane, Bottled water, Trustee, Freddy

LONDON, Oct. 11, 2023 /PRNewswire/ -- New data from the International Burn Injury Database (iBID), shows that burn and scalds to children in the first six months of 2023 increased by 45% compared with the same period in 2022. Burns and scalds to adults and the elderly from hot water bottles have also increased by 19%.

Key Points: 
  • Burns and scalds to adults and the elderly from hot water bottles have also increased by 19%.
  • The Children's Burns Trust and British Burn Association , have released this exclusive insight to raise awareness of the risks posed by hot water bottles and the devastating nature of burns and scalds, which can lead to life-altering injuries.
  • We heard Freddie scream and turned to see that the hot water bottle had split, spilling all over his lap and legs.
  • – Ken Dunn BSc FRCS(Lond) FRCS(plast) FRCS(ed), Vice Chair of Trustees, Consultant Burns and Plastic Surgeon (retired)
    Rubber deteriorates over time so old hot water bottles can burst or leak and cause serious burns.

Hepatitis C: Britons getting tattoos and cosmetic procedures abroad may be at risk – here's how to avoid it

Retrieved on: 
Thursday, September 28, 2023
Amnesia, Infection, Prison, Risk, Hepatitis, Bleeding, HIV, Hepatocellular carcinoma, Liver disease, Myalgia, Decontamination, Fever, Cirrhosis, Brain, Needle, Diarrhea, Hepatitis C, Liver cancer, Vomiting, Bruise, Jaundice, Blood, Recreational drug use, Abdomen, Nausea, Liver, Infant, NHS, Chronic liver disease, Headache, Fatigue, Dentistry, Pharmaceutical industry, Vaccine, Medical device

A growing number of people living in the UK are going abroad to have tattoos, piercings and cosmetic surgeries.

Key Points: 
  • A growing number of people living in the UK are going abroad to have tattoos, piercings and cosmetic surgeries.
  • But people heading abroad for cosmetic procedures may want to be extra cautious – with recent reports suggesting thousands of UK residents may have unknowingly contracted hepatitis C this way.
  • Over 170 million people worldwide are estimated to have hepatitis C. There are approximately one million new infections each year.

What is hepatitis C?

    • In rare cases, hepatitis C can also be spread through sexual intercourse, or from an infected mother to an infant during childbirth.
    • But up to 85% of those infected develop chronic hepatitis – where the virus remains in the body.
    • Hepatitis C is still very treatable in chronic form, though treatments have better outcomes the sooner they’re received.
    • An estimated one in five people with chronic hepatitis C develop a severe liver cancer called hepatocellular carcinoma.

Risk from medical or cosmetic procedures

    • Improper sterilisation also carries risk of other diseases, such as HIV and hepatitis B.
    • Several studies have reported that tattoos done in non-professional settings, such as those received in prisons, carry an increased risk of contracting hepatitis C due to improper sterilisation.
    • Even tattoos done in professional tattoo parlours may carry an increased risk if reusable needles aren’t adequately sterilised between clients.
    • Although data is limited, this risk is probably the same for cosmetic and dental procedures.

How can you avoid it?

    • If in the UK, ask to see the business’s licence to ensure they’re registered with a local council.
    • With any injectable, ideally these should be done by a medical professional – such as a nurse or dentist.
    • If it comes back positive, get treated as soon as possible as hepatitis C virus is a highly treatable infection.

Hinge Health Continues to Advance Women’s Pelvic Care with Breathing Guidance and Smart Trainer Device

Retrieved on: 
Tuesday, September 26, 2023
Consumer Electronics, Technology, Health, Women, Wearables, Mobile Technology, Health Technology, Medical Devices, Apps, Applications, Software, Consumer, Telemedicine, Virtual Medicine, Exercise, DSM-IV codes, Pelvic pain, Pregnancy, Pit additive, Life, Anxiety, Therapy, Incontinence, Woman, Pelvic floor, Abdomen, Weightlifting, Swelling, Menopause, Happiness, Meditation, Research, Mental health, Urinary incontinence, Birth control

Hinge Health’s Pelvic Health Program has seen tremendous adoption and effectiveness with over 15,000 participants enrolling since the program was introduced in May 2023.

Key Points: 
  • Hinge Health’s Pelvic Health Program has seen tremendous adoption and effectiveness with over 15,000 participants enrolling since the program was introduced in May 2023.
  • “For too long, women have been suffering in silence with pelvic conditions, without access to high-quality care,” said Inessa Lurye, Head of Women’s Health at Hinge Health.
  • Breathing Guidance: A new breathing and meditation experience helps members reduce stress and anxiety as well as decrease muscle tension, which can help women address their pelvic health symptoms.
  • Care is personalized around one of four pelvic floor needs: pregnancy and postpartum, bladder control, pelvic pain, and pelvic strength.

New Survey: Chiseled Abs Tops List of Fitness Enthusiasts' Desired Muscular Attributes

Retrieved on: 
Tuesday, September 26, 2023
Abdomen, Male, Obesity, Health, Fitness, Facial muscles, Attention, Female, Muscle & Fitness, Pig

NEW YORK, Sept. 26, 2023 /PRNewswire/ -- A recent survey conducted by Gymless.org polled 285,000 fitness enthusiasts to find out which muscular attributes are most desired. The clear favorite? Chiseled abs, with a whopping 31% of respondents choosing this over other options.

Key Points: 
  • NEW YORK, Sept. 26, 2023 /PRNewswire/ -- A recent survey conducted by Gymless.org polled 285,000 fitness enthusiasts to find out which muscular attributes are most desired.
  • Chiseled abs, with a whopping 31% of respondents choosing this over other options.
  • While other muscular attributes, such as wide shoulders and a V-shaped back, received significant attention, the coveted six-pack stood out as the leading desired body feature.
  • Having a strong bench press or an intimidating front-facing appearance, it would seem, is not a priority for some fitness enthusiasts.

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older

Retrieved on: 
Friday, September 22, 2023
Hereditary angioedema, Face, Marketing, Safety, TAK, European Directive on Traditional Herbal Medicinal Products, Pharmacokinetics, European Medicines Agency, Clinical research associate, European Commission, Genetic disorder, First, Committee, EMA, SPRING, HAE, Patient, Committee for Medicinal Products for Human Use, Abdomen, Diagnosis, Ageing, Throat, Flint Adolescent Study, EC, NYSE, Combination, CHMP, Vaccine, Pharmaceutical industry, Lanadelumab, EU, Takeda

HAE is a Rare, Genetic Disorder Estimated to Affect About 1 in 10,000 to 1 in 50,000 People Worldwide.

Key Points: 
  • HAE is a Rare, Genetic Disorder Estimated to Affect About 1 in 10,000 to 1 in 50,000 People Worldwide.
  • The Condition Results in Recurring Attacks of Oedema (Swelling) in Various Parts of the Body that can be Debilitating and Painful.
  • [4],[5],[6] The European Commission (EC) will consider the CHMP positive opinion and decide upon potential marketing authorization in the coming months.
  • Lanadelumab is currently indicated for the routine prevention of recurrent attacks of HAE in patients aged 12 years and older.

Mindray Introduces Groundbreaking 2-in-1 Handheld Ultrasound Device with Multi-device Connectivity

Retrieved on: 
Thursday, September 7, 2023
Critical care, Emergency medicine, FAST, Workflow, TCI, Wireless, Lung, IOS, POCUS, Abdomen, Atmosphere of Earth, AAA, Hospital, Health, Heart, Medical imaging, Trauma

MAHWAH, N.J., Sept. 7, 2023 /PRNewswire/ -- Mindray, a global leader and developer of healthcare solutions and technologies in ultrasound, patient monitoring, and anesthesia, announced the launch of its TE Air Wireless Handheld Ultrasound, a new imaging solution that improves ultrasound accessibility. This compact, wireless technology enables healthcare professionals to carry comprehensive scanning capabilities in their pockets, adapting to a wide array of clinical scenarios. The TE Air is the industry's first handheld ultrasound device that can connect to either a mobile device or the touch-based TE X Ultrasound System, expanding its utility and accessibility.

Key Points: 
  • Mindray charges ahead and disrupts the point of care market again with its first wireless handheld ultrasound imaging solution expanding utility and accessibility for point of care ultrasound users.
  • MAHWAH, N.J., Sept. 7, 2023 /PRNewswire/ -- Mindray, a global leader and developer of healthcare solutions and technologies in ultrasound, patient monitoring, and anesthesia, announced the launch of its TE Air Wireless Handheld Ultrasound , a new imaging solution that improves ultrasound accessibility.
  • The TE Air is the industry's first handheld ultrasound device that can connect to either a mobile device or the touch-based TE X Ultrasound System , expanding its utility and accessibility.
  • Mindray introduces the first handheld wireless ultrasound that can connect to a mobile device or ultrasound system.

Merit Medical Launches the Aspira® Evacuated Drainage Bottle 

Retrieved on: 
Wednesday, September 6, 2023
Heart, Thoracostomy, Hospital, Drainage, Survival, Cancer, Quality of life, MMSI, Pleural effusion, Pain, Health care, Patient, Aspira, Abdomen, Health, Thoracentesis, Ascites, Medical imaging

SOUTH JORDAN, Utah, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of its Aspira Bottle.

Key Points: 
  • SOUTH JORDAN, Utah, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of its Aspira Bottle.
  • The new evacuated drainage bottle is the latest addition to Merit’s drainage portfolio.
  • The bottle also offers convenience with its ease-of-use and advanced design that requires 23% less storage space than the leading drainage bottle on the market.1 To further optimize patient comfort, the Aspira Bottle allows users to control drainage speed, helping to minimize discomfort and pain associated with high vacuum pressure drainage.
  • “The Aspira Bottle is one more way Merit strives to improve patient care, which includes providing the option of at-home care,” said Fred P. Lampropoulos, Merit Medical’s Chairman and CEO.

BRIXADI® (buprenorphine) Extended-Release Injection for Subcutaneous Use (CIII) is Now Available in the U.S. for the Treatment of Moderate to Severe Opioid Use Disorder

Retrieved on: 
Tuesday, September 5, 2023
REMS, Mitigation, Pharmacy, Buprenorphine, Senior counsel, Health care, Opioid use disorder, Refrigeration, OUD, SL, CIII, Heroin, Stomach, Thigh, Patient, Risk, Abdomen, FDA, Disease, Pharmaceutical industry

PLYMOUTH MEETING, Pa., Sept. 5, 2023 /PRNewswire/ -- Braeburn announces that BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine, is now available in the U.S. BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support.

Key Points: 
  • BRIXADI is the first and only injectable buprenorphine for the treatment of moderate to severe OUD that offers weekly and monthly doses.
  • "Opioid use disorder remains a public health crisis with over 82,000 people dying from an opioid overdose last year," said Mike Derkacz, President and CEO of Braeburn.
  • "We've remained committed to making another option available for healthcare providers to treat their patients with OUD, and the availability of BRIXADI is a significant milestone for Braeburn."
  • BRIXADI is the only buprenorphine injectable that utilizes FluidCrystal®* Injection Depot Technology, allowing for a low volume pre-filled syringe with a thin needle.